Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Marin

Showing results (1-10 of 179) with videos related to

Pageof 18
Sort By:
Current Hematologic Malignancy Reports|February 6, 2013
Management of the new patient with CML in chronic phaseDavid Marin
Hematology. American Society of Hematology. Education Program|December 13, 2012
Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemiaDavid Marin
Seminars in Hematology|September 30, 2010
Current status of imatinib as frontline therapy for chronic myeloid leukemiaDavid Marin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next?David Marin
Current Opinion in Oncology|September 16, 2011
Current opinions and controversies in chronic myeloid leukaemiaBhuvan Kishore, David Marin
The New England Journal of Medicine|January 3, 2019
Allogeneic BK Virus-Specific T Cells for PMLKatayoun Rezvani, David Marin
Clinical Lymphoma & Myeloma|December 3, 2009
Dasatinib and chronic myeloid leukemia: two-year follow-up in eight clinical trialsJirí Pavlů, David Marin
Seminars in Hematology|February 4, 2003
Management decisions in chronic myeloid leukemiaJohn M Goldman, David Marin
Oncology (Williston Park, N.Y.)|November 27, 2012
Is imatinib still an acceptable first-line treatment for CML in chronic phase?John M Goldman, David Marin
Expert Review of Anticancer Therapy|May 10, 2005
Personalized medical treatment strategies for patients with chronic myeloid leukemiaCatherine Burton, David Marin, Jane Apperley
Pageof 18

Showing results (1-10 of 179) with videos related to

Sort By:
Pageof 18
Current Hematologic Malignancy Reports|February 6, 2013
Management of the new patient with CML in chronic phaseDavid Marin
Hematology. American Society of Hematology. Education Program|December 13, 2012
Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemiaDavid Marin
Seminars in Hematology|September 30, 2010
Current status of imatinib as frontline therapy for chronic myeloid leukemiaDavid Marin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next?David Marin
Current Opinion in Oncology|September 16, 2011
Current opinions and controversies in chronic myeloid leukaemiaBhuvan Kishore, David Marin
The New England Journal of Medicine|January 3, 2019
Allogeneic BK Virus-Specific T Cells for PMLKatayoun Rezvani, David Marin
Clinical Lymphoma & Myeloma|December 3, 2009
Dasatinib and chronic myeloid leukemia: two-year follow-up in eight clinical trialsJirí Pavlů, David Marin
Seminars in Hematology|February 4, 2003
Management decisions in chronic myeloid leukemiaJohn M Goldman, David Marin
Oncology (Williston Park, N.Y.)|November 27, 2012
Is imatinib still an acceptable first-line treatment for CML in chronic phase?John M Goldman, David Marin
Expert Review of Anticancer Therapy|May 10, 2005
Personalized medical treatment strategies for patients with chronic myeloid leukemiaCatherine Burton, David Marin, Jane Apperley
Pageof 18